SAINT LAURENT, Quebec, Dec. 22, 2011 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCBB:IGXT) (“IntelGenx”) today announced that it has received a No Objection Letter (“NOL”) from Health Canada for the commencement of a pivotal clinical trial to be conducted with IntelGenx’ proprietary VersaFilm oral thin film technology for the rapid relief of migraine.
